Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer

Marcus Hentrich Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Munich, GermanyCorrespondence[email protected]

Xaver Schiel Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Munich, Germany

Birgit Scheidt Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Munich, Germany

Michael Reitmeier Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Munich, Germany

Ulrike Hoffmann Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Munich, Germany

Ludwig Lutz Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Munich, Germany

References

Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol 2006; 18: 773–80
PubMed Web of Science ®Google Scholar
Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856–65
PubMed Web of Science ®Google Scholar
Boisseau M, Bugat R, Mahioubi M. Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment wit irinotecan (CPT-11). Eur J Cancer 1996; 32A: 737–8
PubMed Web of Science ®Google Scholar
Oztop I, Demirkan B, Yaren A, Tarhan O, Sengul B, Ulukus C, et al. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucovorin and irinotecan. Tumori 2004; 90: 514–6
PubMed Web of Science ®Google Scholar
He AR, Marshall J. Biologic therapy for colon cancer. Clin Adv Hematol Oncol 2005; 3: 555–61
PubMedGoogle Scholar
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. New Engl J Med 2005; 352: 476–87
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date